PROVIDENCE, R.I.--(BUSINESS WIRE)--Beech Tree Labs, Inc. announced today that it has completed a successful Phase 2a clinical evaluation of its novel therapeutic agent, UISH001, for treating urinary incontinence (UI). This FDA-authorized study was a multi-site, 67-patient, placebo-controlled trial.